{
    "clinical_study": {
        "@rank": "105726", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the safety and efficacy of Xeloda\n      (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer.\n      Patients will be followed until disease progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Metastatic colorectal cancer\n\n          -  Receiving Xeloda according to registered indication\n\n        Exclusion Criteria:\n\n          -  Patients who are not eligible for Xeloda treatment according to the Summary of\n             Product Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic colorectal cancer"
            }
        }, 
        "enrollment": {
            "#text": "259", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697462", 
            "org_study_id": "ML22585"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kragujevac", 
                        "country": "Serbia", 
                        "zip": "34000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "NIS", 
                        "country": "Serbia", 
                        "zip": "18000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sremska Kamenica", 
                        "country": "Serbia", 
                        "zip": "21204"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Serbia"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Serbia: Medicines and Medical Devices Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety monitoring: Occurrence of Hand Foot Syndrome as predictive factor", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}